MedTrace Logo

Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

NCT03376672 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-04-03

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of 3-drug all-oral combination, ixazomib plus lenalidomide plus dexamethasone (IRd) as induction treatment for autologous stem cell transplantation eligible patients followed by IRd consolidation and risk based maintenance treatment with IR or R alone.

Conditions

Interventions

DRUG

Ixazomib

All patients will have similar induction and consolidation treatment with the same regimen.

DRUG

Lenalidomide

All patients will have similar induction and consolidation treatment with the same regimen.

DRUG

Dexamethasone

All patients will have similar induction and consolidation treatment with the same regimen.

Sponsors & Collaborators

  • Nordic Myeloma Study Group

    collaborator OTHER

  • Celgene

    collaborator INDUSTRY

  • Takeda

    collaborator INDUSTRY

  • Raija Silvennoinen

    lead OTHER

Principal Investigators

  • Raija H Silvennoinen, MD, PhD · Helsinki University Central Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-31
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Finland
  • Lithuania
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03376672 on ClinicalTrials.gov